Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.
MetadataShow full item record
<b/> BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558-60. ©2017 AACR.See related article by van Geel et al., p. 610.
Version of record
Antineoplastic Combined Chemotherapy Protocols
Mitogen-Activated Protein Kinases
Molecular Targeted Therapy
Proto-Oncogene Proteins B-raf
Medicine Drug Development Unit (de Bono)
License start date
Cancer Discov, 2017, 7 (6), pp. 558 - 560